argenx’s VYVGART Shows Clinically Meaningful Benefit in Phase 3 Myositis Study, Stock Jumps
argenx’s efgartigimod met primary endpoint in Phase 3 ALKIVIA trial for autoimmune myositis, showing 15.4-point TIS improvement at Week 52.
/ 491 items
#XY Event-Driven Stocks↓
Skye Becomes a Shell for Redx: $125 Million Deal Hands Control to UK Fibrosis Company
Skye Bioscience acquires Redx Pharma via UK scheme of arrangement. Combined company Fibrx focuses on RXC008 for Crohn’s fibrosis. Skye holders get only 5.38%.
Valneva’s Lyme Disease Vaccine Candidate Clears Key EMA Hurdle
Valneva shares surge after EMA validates its Lyme disease vaccine candidate developed with Pfizer. Phase 3 trial showed over 70% efficacy.
PTC Acquires Near-Approval ST-920 Fabry Gene Therapy in Bankruptcy Auction
PTC Therapeutics acquires BLA-stage ST-920, a one-time AAV gene therapy for Fabry disease, with potential U.S. launch in 2027 and strong clinical data.
Mixed News for Neurocrine: Strong TD Data for INGREZZA, Caution on Vykat XR
Neurocrine reports strong KINECT-PRO results for INGREZZA in tardive dyskinesia quality of life, while experts flag safety risks for Vykat XR.
Cencora Reaffirms Guidance After Limited Walgreens Volume Shift
Cencora reaffirms $17.75–$17.95 FY2026 EPS after minor Walgreens volume shift. Analysts see just 3–3.5% impact as core prime vendor deal stays intact.